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Antibacterial activity of Ionic Liquids based on
ampicillin against resistant bacteria
Ricardo Ferraz,*ab Vaˆnia Teixeira,b De´bora Rodrigues,b Ru´ben Fernandes,bc
Cristina Prudeˆncio,bc Joa˜o Paulo Noronha,a Zˇeljko Petrovski*a and Lu´ıs C. Branco*a
Antibacterial activities of novel Active Pharmaceutical Ingredient Ionic Liquids (API–ILs) based on ampicillin
anion [Amp] have been evaluated. They showed growth inhibition and bactericidal properties on some
sensitive bacteria and especially some Gram-negative resistant bacteria when compared to the
[Na][Amp] and the initial bromide and chloride salts. For these studies were analysed the minimum
inhibitory concentration (MIC) and minimum bactericidal concentration (MBIC) against sensitive Gram-
negative bacteria Escherichia coli ATCC 25922 and Klebsiella pneumoniae (clinically isolated), as well as
sensitive Gram positive Staphylococcus Aureus ATCC 25923, Staphylococcus epidermidis and
Enterococcus faecalis and completed using clinically isolated resistent strains such as E. coli TEM CTX
M9, E. coli CTX M2 and E. coli AmpC MOX. From the obtained MIC values of studied API–ILs and
standard [Na][Amp] were derived RDIC values (relative decrease of inhibitory concentration). High RDIC
values of [C16Pyr][Amp] especially against two resistant Gram-negative strains E. coli TEM CTX M9 (RDIC
>1000) and E. coli CTX M2 (RDIC >100) point clearly to a potential promising role of API–ILs as
antimicrobial drugs in particular against resistant bacterial strains.
Introduction
Ionic liquids (ILs) are usually dened as organic salts with
melting points lower than 100 C (several of them are liquid at
room temperature).1 They became popular due to the large
number of possible cation/anion combinations allowing
diﬀerent tunable interactions and potential applications. Some
IL properties such as their high thermal and chemical stability,
negligible vapor pressure,2 high ionic conductivity, lack of
inammability and adjustable solubility have attracted
numerous applications across an extensive variety of research
areas3 in particular related with organic chemistry, chemical
engineering, material science, physical chemistry, analytical
chemistry and biotechnology, among others.
One of the most promising applications of ILs seems to be
the so-called third generation of ILs (their arrangement with
active pharmaceutical ingredients, APIs) or API–ILs.4 It is sug-
gested that these compounds can solve problems associated to
pharmaceutical industry related with polymorphism and drug
solubility.4 At the beginning, the uses of ILs in the biosciences
were diﬃcult because of ILs toxicity,5 however more recently it
was shown lower inherent toxicity and thus a lower impact on
human health and the environment from some hydrophobic
ILs derived from toxic herbicides.5 Presently biocidal properties
of large cations, such as benzalkonium and imidazolium
species, are also largely used as an advantage, to kill or inhibit
bacteria6 or yeast7 growth. In respect to this area, diﬀerent
publications reported antimicrobial activity studies using
microorganisms or cell culture for long alkyl chain quaternary
ammonium.8 Recently, Cole and co-workers9 reported the use of
metathesis reaction to produce ILs with long alkyl chain
quaternary ammonium and ampicillin anion. Some ILs have
been eﬃciently tested with clinically signicant microbial
pathogens, including Methicillin-resistant Staphylococcus
aureus (MRSA).10
Bacterial resistance to diﬀerent antibiotics that are
commercially available is one of the major public health prob-
lems.11 Recent outbreaks of E. coli O104 (ref. 12) in Germany as
well as the emergence of multi-drug resistant organisms such as
Gram-negative Enterobacteriaceae associated to the New Delhi
metallo b-lactamase13 conrm that this is a remarkable problem
for public health, but also at an economic and social point of
view. Besides the fact that bacterial resistance increases the
mortality and the morbidity some recent publications have
reported the nancial burden of health care-associated infec-
tions (HAIs) in the USA.14
Innovative therapies involving the use of ILs as a drug
delivery platform suggest others attractive opportunities for
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